Jul. 13 at 11:34 AM
$AQST Libervant’s competitor Valtoco looses their orphan drug block in just 6 short months. In the meantime here is a snap shot of Libervant’s potential future earnings based on Valtoco’s earnings.
“VALTOCO generates approximately
$295 to
$300 million in annual net revenue. This milestone for the diazepam nasal spray was announced by its manufacturer, Neurelis, alongside an expanded FDA label for children ages 2 to 5 and new patents that extend its market exclusivity.”
